The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease
Open accessAbstract
RATIONALE: The oral phosphodiesterase-4 (PDE4) inhibitor, roflumilast, can improve lung function in moderate chronic obstructive pulmonary disease (COPD). Whether treatment is effective in more severe COPD (GOLD [Global Initiative for Chronic Obstructive Lung Disease] stages III and IV) over a longer period is unknown. OBJECTIVES: To determine whether roflumilast improves lung function and decreases exacerbation frequency over 1 year in patients with stable COPD. METHODS: We conducted a randomized, placebo-controlled, double-blind, parallel-group trial for 1 year. We recruited 1,513 patients (mean post-bronchodilator FEV1 41% predicted), 760 receiving oral 500 microg roflumilast and 753 receiving placebo once daily. MEASUREMENTS AND MAIN RESULTS: We recorded post-bronchodilator FEV1, exacerbation rate, St. George's Respiratory Questionnaire total score at the study end point, and number and type of reported adverse events during treatment. Post-bronchodilator FEV1 increased by 39 ml with roflumilast compared with placebo by 52 weeks (p=0.001). The mean exacerbation rate was low and comparable in both treatment groups (0.86 vs. 0.92 exacerbations/patient/yr for roflumilast and placebo, respectively). In a retrospective analysis, the exacerbation rate in patients in GOLD stage IV disease was 36% lower in patients treated with roflumilast than in those treated with placebo (1.01 vs. 1.59 exacerbations/patient/year, respectively; p=0.024). The St. George's Respiratory Questionnaire total score did not differ between treatments. The commonest adverse events related to roflumilast treatment were diarrhea, nausea, and headache, which usually subsided during continued treatment. However, roflumilast resulted in more withdrawals within the first 3 to 4 weeks of administration. CONCLUSIONS: In severe, stable COPD, PDE4 inhibition with roflumilast produced a modest but significant improvement in lung function without changing the exacerbation rate or health status. However, patients with very severe disease experienced fewer exacerbations with roflumilast.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Self-citationMurray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07492-2 · Cited by 7,007
Standardization of Spirometry, 1994 Update. American Thoracic Society.
(1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.152.3.7663792 · Cited by 6,594
Lung volumes and forced ventilatory flows
Quanjer, P. H., Tammeling, G. J., Cotes, J. E., Pedersen, O. F., Peslin, R., & Yernault, J.-C. (1993) · European Respiratory Journal · doi:10.1183/09041950.005s1693 · Cited by 5,318
(1993) · PubMed · Cited by 3,827
Jones, P. W., Quirk, F. H., Baveystock, C. M., & Littlejohns, P. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.6.1321 · Cited by 3,035
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Chronic obstructive pulmonary disease: molecular and cellularmechanisms
Barnes, P. J., Shapiro, S. D., & Pauwels, R. A. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00040703 · Cited by 1,439
Calverley, P., Pauwels, R., Vestbo, J., Jones, P., Pride, N., Gulsvik, A., Anderson, J., & Maden, C. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12459-2 · Cited by 1,221
Self-citationBurden and clinical features of chronic obstructive pulmonary disease (COPD)
Pauwels, R. A., & Rabe, K. F. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16855-4 · Cited by 1,004
Bourbeau, J. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.5.585 · Cited by 939
Szafranski, W., Cukier, A., Ramirez, A., Menga, G., Sansores, R., Nahabedian, S., Peterson, S., & Olsson, H. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00031402 · Cited by 887
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease
Casaburi, R., Mahler, D. A., Jones, P. W., Wanner, A., San Pedro, G., ZuWallack, R. L., Menjoge, S. S., Serby, C. W., & Witek, T. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00269802 · Cited by 881
Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease
Calverley, P. M., Boonsawat, W., Cseke, Z., Zhong, N., Peterson, S., & Olsson, H. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00027003 · Cited by 730
Self-citationEpidemiology and costs of chronic obstructive pulmonary disease
Chapman, K. R., Mannino, D. M., Soriano, J. B., Vermeire, P. A., Buist, A. S., Thun, M. J., Connell, C., Jemal, A., Lee, T. A., Miravitlles, M., et al. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00024505 · Cited by 704
COPD exacerbations: definitions and classifications
Burge, S., & Wedzicha, J. A. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00078002 · Cited by 664
ITO, K., LIM, S., CARAMORI, G., CHUNG, K. F., BARNES, P. J., & ADCOCK, I. M. (2001) · The FASEB Journal · doi:10.1096/fj.00-0432fje · Cited by 481
Rabe, K. F., Bateman, E. D., O'Donnell, D., Witte, S., Bredenbröker, D., & Bethke, T. D. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67100-0 · Cited by 475
Donohue, J. F., van Noord, J. A., Bateman, E. D., Langley, S. J., Lee, A., Witek, T. J., Kesten, S., & Towse, L. (2002) · Chest · doi:10.1378/chest.122.1.47 · Cited by 471
Impact of preventing exacerbations on deterioration of health status in COPD
Spencer, S., Calverley, P. M. A., Burge, P. S., & Jones, P. W. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00121404 · Cited by 441
Self-citationCOPD exacerbations {middle dot} 2: Aetiology
Sapey, E. (2006) · Thorax · doi:10.1136/thx.2005.041822 · Cited by 437
Interpreting COPD Prevalence Estimates
Halbert, R. J., Isonaka, S., George, D., & Iqbal, A. (2003) · Chest · doi:10.1378/chest.123.5.1684 · Cited by 389
Alsaeedi, A., Sin, D. D., & McAlister, F. A. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01143-9 · Cited by 326
van der Valk, P., Monninkhof, E., van der Palen, J., Zielhuis, G., & van Herwaarden, C. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200206-512oc · Cited by 298
Chronic obstructive pulmonary disease
(2019) · Demonstrating Your Clinical Competence in Respiratory Disease, Diabetes and Dermatology · doi:10.1201/9781315365176-10 · Cited by 235
Gamble, E. A., Grootendorst, D. C., Brightling, C. E., Troy, S., Qiu, Y., Zhu, J., Parker, D., Matin, D., Majumdar, S., Vignola, A. M., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200212-1490oc · Cited by 213
Chronic obstructive pulmonary disease
Calverley, P., & Walker, P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14416-9 · Cited by 210
Self-citationCompton, C. H., Gubb, J., Nieman, R., Edelson, J., Amit, O., Bakst, A., Ayres, J. G., Creemers, J. P., Schultze-Werninghaus, G., Brambilla, C., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05481-2 · Cited by 208
SWANNEY, M. P., JENSEN, R. L., CRICHTON, D. A., BECKERT, L. E., CARDNO, L. A., & CRAPO, R. O. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.3.9907115 · Cited by 196
Fishman, G. S., & Moore, L. R. (1982) · Journal of the American Statistical Association · doi:10.1080/01621459.1982.10477775 · Cited by 159
Rolipram in Major Depressive Disorder: Results of a Double-Blind Comparative Study with Imipramine
Hebenstreit, G. F., Fellerer, K., Fichte, K., Fischer, G., Geyer, N., Meya, U., Sastre-y-Hernández, M., Schöny, W., Schratzer, M., Soukop, W., et al. (1989) · Pharmacopsychiatry · doi:10.1055/s-2007-1014599 · Cited by 159
Rennard, S. I., Schachter, N., Strek, M. E., Rickard, K., & Amit, O. (2006) · CHEST Journal · doi:10.1378/chest.129.1.56 · Cited by 113
Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD)
Barnette, M. S. (1999) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8735-9_5 · Cited by 98
Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease
Soto, F. J., & Hanania, N. A. (2005) · Current Opinion in Internal Medicine · doi:10.1097/01.mcp.0000151715.58124.9e · Cited by 47
Rennard, S. I., Schachter, N. S., Strek, M. E., RICKARD, K. A., & Amit, O. (2006) · Respiratory Medicine COPD Update · doi:10.1016/j.rmedu.2006.03.037 · Cited by 29
Muise, E. S., Chute, I. C., Claveau, D., Masson, P., Boulet, L., Tkalec, L., Pon, D. J., Girard, Y., Frenette, R., & Mancini, J. A. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00903-6 · Cited by 24
Roflumilast for chronic obstructive pulmonary disease – Author's reply
Rabe, K. F. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67751-3 · Cited by 6
Cited by
Systemic manifestations and comorbidities of COPD
Barnes, P. J., & Celli, B. R. (2009) · European Respiratory Journal · doi:10.1183/09031936.00128008 · Cited by 1,820
COPD exacerbations: Defining their cause and prevention
Wedzicha, J. A., & Seemungal, T. A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61382-8 · Cited by 1,370
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
Calverley, P. M., Rabe, K. F., Goehring, U.-M., Kristiansen, S., Fabbri, L. M., & Martinez, F. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61255-1 · Cited by 829
Self-citationManagement of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline
Wedzicha, J. A., Miravitlles, M., Hurst, J. R., Calverley, P. M. A., Albert, R. K., Anzueto, A., Criner, G. J., Papi, A., Rabe, K. F., Rigau, D., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00791-2016 · Cited by 683
Self-citationFabbri, L. M., Calverley, P. M., Izquierdo-Alonso, J. L., Bundschuh, D. S., Brose, M., Martinez, F. J., & Rabe, K. F. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61252-6 · Cited by 614
Self-citation
Metadata
- Authors
- Calverley, P. M. A., Sanchez-Toril, F., McIvor, A., Teichmann, P., Bredenbroeker, D., & Fabbri, L. M.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-07-15
- Volume
- 176
- Issue
- 2
- Pages
- 154-161
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2151950207
- Cited by
- 325
- References
- 38
- FWCI
- 20.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.